Welcome to the 9th EAPS Congress Programme Scheduling
The congress will officially run on Barcelona Time (GMT+2)
To convert the congress times to your local time Click Here
DESENSITIZATION IN ETOPOSIDE HYPERSENSITIVITY: A CASE REPORT
- Imyadelna Ibma Nila Utama (Indonesia)
Abstract
Background and Aims
Etoposide is a cytotoxic agent, which has been used in the treatment of a variety of malignant conditions. Hypersensity reactions to etoposide have been reported from 2% to 51%. The aim for this study is to report the outcome of a patient who underwent etoposide desensitization protocol.
Methods
All the data was collected from the electronic medical record.
Results
A 15-year-old girl with left germ cell tumor of ovarium stage IV was admitted for chemotheraphy. The patient has no history of drugs or food allergies. During the first administration of etoposide the patients experienced generalized erythematous rashes, chest pain, shortness of breath and palpitations. The infusion was stopped immediately and she was treated as an anaphylaxis reaction. The patient must receive five courses of etoposide consequently. Because there is no alternative drug, we administered etoposide using the modified six-step etoposide desensitization by Winifred. The desensitization started with 0.01% dose of etoposide along with steroid and antihistamine as premedication. On the next day, the patient received etoposid in a continuous drip for 10 hours at concentration of 0.2 mg/mL. The drugs successfully administered without any adverse event.
Conclusions
Six step etoposide desensitization can be used for a patient who had experienced etoposide hypersensitivity reaction.